Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,546,721 shares of the biopharmaceutical company's stock after buying an additional 198,528 shares during the quarter. Price T Rowe Associates Inc. MD owned about 0.28% of Gilead Sciences worth $327,612,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. FMR LLC raised its stake in shares of Gilead Sciences by 21.6% in the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after buying an additional 7,157,113 shares during the period. Wellington Management Group LLP raised its stake in shares of Gilead Sciences by 3.1% in the fourth quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock worth $3,293,822,000 after buying an additional 1,058,331 shares during the period. Geode Capital Management LLC raised its stake in shares of Gilead Sciences by 2.7% in the fourth quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock worth $2,608,337,000 after buying an additional 749,047 shares during the period. Norges Bank bought a new stake in Gilead Sciences during the 4th quarter valued at approximately $1,789,254,000. Finally, Invesco Ltd. lifted its holdings in Gilead Sciences by 12.9% in the 4th quarter. Invesco Ltd. now owns 11,277,915 shares of the biopharmaceutical company's stock worth $1,041,741,000 after purchasing an additional 1,292,399 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Up 3.1 %

Shares of NASDAQ:GILD traded up $3.17 during trading hours on Monday, hitting $106.34. The company's stock had a trading volume of 9,453,782 shares, compared to its average volume of 7,514,594. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The company has a market capitalization of $132.41 billion, a price-to-earnings ratio of 287.41, a P/E/G ratio of 0.71 and a beta of 0.32. The firm's fifty day moving average price is $109.19 and its 200 day moving average price is $98.48.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same quarter in the previous year, the business posted ($1.32) EPS. The company's quarterly revenue was down .3% compared to the same quarter last year. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.97%. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 137,676 shares of the company's stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $102.22, for a total transaction of $14,073,240.72. Following the transaction, the chief financial officer now owns 171,223 shares in the company, valued at approximately $17,502,415.06. This represents a 44.57 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold a total of 302,785 shares of company stock worth $30,540,875 in the last 90 days. 0.27% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently commented on GILD shares. Morgan Stanley boosted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday. DZ Bank raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and boosted their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Finally, Bank of America boosted their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $109.43.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.